The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients - The EUGENE2 study

Abstract

Aims/hypothesis: A recent genome-wide association study identified the SLC30A8 rs13266634 polymorphism encoding an Arg325Trp polymorphism in the zinc transporter protein member 8 (ZnT-8) to be associated with type 2 diabetes. Here, we investigate whether the polymorphism is related to altered insulin release in response to intravenous and oral glucose loads in non-diabetic offspring of type 2 diabetic patients. Methods: We genotyped SLC30A8 rs13266634 in 846 non-diabetic offspring of type 2 diabetic patients from five different white populations: Danish (n=271), Finnish (n=217), German (n=149), Italian (n =109) and Swedish (n=100). Participants were subjected to both IVGTTs and OGTTs, and measurements of insulin sensitivity. Results: Homozygous carriers of the major type 2 diabetes C risk-allele showed a 19% decrease in first-phase insulin release (0-10 min) measured during the IVGTT (CC 3,624±3,197; CT 3,763±2,674; TT 4,478±3,032 pmol l-1 min-1, mean±SD; p=0.007). We found no significant genotype effect on insulin release measured during the OGTT or on estimates of insulin sensitivity. Conclusions/interpretation: Of European non-diabetic offspring of type 2 diabetes patients, 46% are homozygous carriers of the Arg325Trp polymorphism in ZnT-8, which is known to associate with type 2 diabetes. These diabetes-prone offspring are characterised by a 19% decrease in first-phase insulin release following an intravenous glucose load, suggesting a role for this variant in the pathogenesis of pancreatic beta cell dysfunction. © 2008 Springer-Verlag.